Pharmacogenomics of Statin Responsiveness

This publication has 42 references indexed in Scilit:

• Gender-specific effects of estrogen receptor α gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism
  Atherosclerosis, 2005
• Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
  Atherosclerosis, 2004
• A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
  Journal of Human Genetics, 2004
• Lipid-lowering response to statins is affected by CYP3A5 polymorphism
  Pharmacogenetics, 2004
• High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
  Pharmacogenetics, 2004
• Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
  The American Journal of Cardiology, 2004
• ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin
  Journal of Lipid Research, 2004
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• The genetic basis of variability in drug responses
  Nature Reviews Drug Discovery, 2002
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998